مباشر

FierceBiotechMadrigal continues MASH deal spree with $1B biobucks license for Arrowhead asset rejected by J&J Endpoints NewsSwiss manufacturing, biotech industry so far unfazed by geopolitics Endpoints NewsPfizer ends Trillium-related development as R&D spend jumps Endpoints NewsMicrobiome startup raises $48M for immunotherapy and malnutrition treatments Endpoints NewsJ&J's IBD combo fails Phase 2 studies, but will move into pivotal testing FierceBiotechPfizer’s $2.3B Trillium bet ends in failure as remaining CD47 blocker scrapped along with T-cell engager FierceBiotechSanofi expands AI capabilities, investing $294M to scale Toronto hub Endpoints NewsMadrigal extends MASH deal streak with Arrowhead drug that J&J didn't want Endpoints NewsHealthcare organizations are increasingly building their own AI tools PharmaVoiceWhat’s at stake in Amgen’s showdown with the FDA?BioWorldGenosco discloses GSPT protein degraders BioWorldDeepcure develops new BRD4 BD2 inhibitors

Promega Blog ٥ مايو ٢٠٢٦

Beyond the Liver: How Liposomal LNPs Are Expanding the Reach of mRNA Delivery

Introduction Lipid nanoparticles (LNPs) have transformed mRNA delivery. From COVID-19 vaccines to the first approved RNAi therapeutic, ONPATTRO (Patisiran), LNP...

Introduction Lipid nanoparticles (LNPs) have transformed mRNA delivery. From COVID-19 vaccines to the first approved RNAi therapeutic, ONPATTRO (Patisiran), LNPs have proven their ability to ferry nucleic acid cargo into cells with speed and efficiency (Huang, 2019). Despite this transformation, most clinically deployed LNP formulations share a significant constraint: following intravenous administration, roughly 90% of […] The post Beyond the Liver: How Liposomal LNPs Are Expanding the Reach of mRNA Delivery appeared first on Promega Connections .